Capstone Investment Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$673K Sell
2,300
-1,000
-30% -$329K ﹤0.01% 1011
2025
Q4
$1.16M Sell
3,300
-1,900
-37% -$642K ﹤0.01% 816
2025
Q3
$1.68M Buy
5,200
+1,500
+41% +$467K ﹤0.01% 830
2025
Q2
$1.44M Sell
3,700
-700
-16% -$282K ﹤0.01% 747
2025
Q1
$1.91M Sell
4,400
-6,300
-59% -$2.53M 0.01% 695
2024
Q4
$3.95M Buy
10,700
+2,400
+29% +$1M 0.01% 630
2024
Q3
$4.32M Buy
8,300
+1,800
+28% +$962K 0.01% 500
2024
Q2
$3.52M Buy
6,500
+1,300
+25% +$687K 0.01% 550
2024
Q1
$2.7M Sell
5,200
-7,000
-57% -$3.48M 0.01% 658
2023
Q4
$5.75M Buy
12,200
+2,900
+31% +$1.34M 0.02% 488
2023
Q3
$4.05M Buy
9,300
+700
+8% +$318K 0.02% 490
2023
Q2
$3.82M Buy
8,600
+400
+5% +$185K 0.02% 454
2023
Q1
$3.77M Sell
8,200
-1,500
-15% -$714K 0.02% 434
2022
Q4
$4.98M Buy
9,700
+1,200
+14% +$609K 0.04% 388
2022
Q3
$3.86M Sell
8,500
-1,400
-14% -$670K 0.02% 482
2022
Q2
$4.78M Sell
9,900
-24,400
-71% -$12.1M 0.02% 423
2022
Q1
$16.8M Sell
34,300
-13,300
-28% -$6.08M 0.05% 300
2021
Q4
$22.1M Buy
47,600
+7,700
+19% +$3.24M 0.04% 409
2021
Q3
$14.9M Buy
39,900
+6,200
+18% +$2.36M 0.03% 501
2021
Q2
$12.9M Buy
33,700
+2,900
+9% +$1.11M 0.03% 458
2021
Q1
$11.1M Sell
30,800
-3,700
-11% -$1.19M 0.03% 441
2020
Q4
$11.1M Sell
34,500
-700
-2% -$215K 0.04% 376
2020
Q3
$9.45M Buy
35,200
+4,300
+14% +$1.16M 0.05% 343
2020
Q2
$8.13M Buy
30,900
+2,100
+7% +$560K 0.05% 304
2020
Q1
$6.54M Sell
28,800
-8,500
-23% -$2.32M 0.11% 210
2019
Q4
$11.3M Buy
37,300
+10,600
+40% +$2.92M 0.06% 333
2019
Q3
$6.41M Buy
26,700
+8,900
+50% +$2.44M 0.04% 382
2019
Q2
$5.02M Buy
17,800
+6,700
+60% +$1.83M 0.04% 456
2019
Q1
$3.19M Buy
11,100
+5,700
+106% +$1.65M 0.03% 471
2018
Q4
$1.42M Buy
5,400
+2,900
+116% +$797K 0.02% 522
2018
Q3
$685K Buy
+2,500
New +$649K 0.01% 707

Other funds holding ELV

Capstone Investment Advisors's ELV Position: Q1 2026 in Review

Capstone Investment Advisors sold out of Elevance Health (ELV) in Q1 2026, closing a stake of 2,445 shares — an estimated $804K sold.

Capstone Investment Advisors first reported a position in ELV in Q2 2016 and held it in 30 quarters. The position peaked at $7.63M in Q4 2024. 1,466 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Capstone Investment Advisors reported no remaining Elevance Health position as of Q1 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 2,445 Elevance Health shares in Q1 2026, an estimated $804K.
  • Capstone Investment Advisors first reported a position in Elevance Health in Q2 2016 and held it in 30 quarters.
  • Capstone Investment Advisors's Elevance Health position peaked at $7.63M in Q4 2024.
  • 1,466 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.